[
    [
        {
            "time": "2021-08-30",
            "original_text": "上海医药：摩根士丹利、富达国际投资等38家机构于8月30日调研我司",
            "features": {
                "keywords": [
                    "上海医药",
                    "摩根士丹利",
                    "富达国际投资",
                    "机构调研"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "上海医药：摩根士丹利、富达国际投资等38家机构于8月30日调研我司",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-08-31",
            "original_text": "上海医药(601607)控股股东完成增持H股股份5257万股，占比达1.857%",
            "features": {
                "keywords": [
                    "上海医药",
                    "上实集团",
                    "增持",
                    "H股"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(601607)控股股东完成增持H股股份5257万股，占比达1.857%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-31",
            "original_text": "上海医药：上实集团累计增持1.857%股份，增持实施完毕",
            "features": {
                "keywords": [
                    "上海医药",
                    "上实集团",
                    "增持",
                    "股份"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药：上实集团累计增持1.857%股份，增持实施完毕",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-31",
            "original_text": "上海医药(601607)2021年中报点评：业绩超出预期，创新药管线加速扩张",
            "features": {
                "keywords": [
                    "上海医药",
                    "中报",
                    "业绩超出预期",
                    "创新药管线"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(601607)2021年中报点评：业绩超出预期，创新药管线加速扩张",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-08-31",
            "original_text": "A股头条：中国有色金属工业协会喊话铝价投机者",
            "features": {
                "keywords": [
                    "中国有色金属工业协会",
                    "铝价",
                    "投机者"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "有色金属"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A股头条：中国有色金属工业协会喊话铝价投机者",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]